Kast et al. analyzed serum samples from 187 ovarian cancer patients and observed that serum IL-7 levels were significantly higher in patients with advanced-stage ovarian cancer (FIGO III/IV) than in those with early-stage disease (I/II) [19, 20]. This evidence concerns the gene IL7 and ovarian carcinoma.